Bharat Biotech ramping up Covaxin production capacity
Company plans to produce an additional 200 million doses of Covaxin per annum in the GMP facilities located at Ankleshwar, Gujarat, starting from the fourth quarter of 2021
Hyderabad: Hyderabad-based Bharat Biotech announced its quick ramp up of additional manufacturing capacities for Covaxin, at Chiron Behring Vaccines, Ankleshwar, Gujarat, a wholly owned subsidiary of Bharat Biotech.
The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology. Product availability at Ankleshwar to commence from the fourth quarter of 2021.
Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses, adding Chiron BehringChiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture Covaxin.
This effectively takes the volumes up to one billion doses per annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety, the company said.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
